200,000+ products from a single source!
sales@angenechem.com
Home > Sulfanilamide > 1197-22-4
1197-22-4 | Methanesulfonamide, N-phenyl-
CAS No: 1197-22-4 Catalog No: AG000PGW MDL No:MFCD00043782
Product Description
Catalog Number:
AG000PGW
Chemical Name:
Methanesulfonamide, N-phenyl-
CAS Number:
1197-22-4
Molecular Formula:
C7H9NO2S
Molecular Weight:
171.2169
MDL Number:
MFCD00043782
IUPAC Name:
N-phenylmethanesulfonamide
InChI:
InChI=1S/C7H9NO2S/c1-11(9,10)8-7-5-3-2-4-6-7/h2-6,8H,1H3
InChI Key:
LBTPIFQNEKOAIM-UHFFFAOYSA-N
SMILES:
CS(=O)(=O)Nc1ccccc1
EC Number:
601-626-2
NSC Number:
11329
Properties
Complexity:
199
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
171.035g/mol
Formal Charge:
0
Heavy Atom Count:
11
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
171.214g/mol
Monoisotopic Mass:
171.035g/mol
Rotatable Bond Count:
2
Topological Polar Surface Area:
54.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
0.9
Literature
| Title | Journal |
|---|---|
| Iguratimod: a new disease-modifying antirheumatic drug. | Drugs of today (Barcelona, Spain : 1998) 20120901 |
| Highly potent macrocyclic BACE-1 inhibitors incorporating a hydroxyethylamine core: design, synthesis and X-ray crystal structures of enzyme inhibitor complexes. | Bioorganic & medicinal chemistry 20120715 |
| Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. | TheScientificWorldJournal 20120101 |
| Pharmacological management of atrial fibrillation: one, none, one hundred thousand. | Cardiology research and practice 20110101 |
| In silico analysis of conformational changes induced by mutation of aromatic binding residues: consequences for drug binding in the hERG K+ channel. | PloS one 20110101 |
| Stereoselective Inhibition of the hERG1 Potassium Channel. | Frontiers in pharmacology 20100101 |
| Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel. | Biochemical pharmacology 20090515 |
| Non-vanillyl resiniferatoxin analogues as potent and metabolically stable transient receptor potential vanilloid 1 agonists. | Bioorganic & medicinal chemistry 20090115 |
| Discovery of a novel activator of KCNQ1-KCNE1 K channel complexes. | PloS one 20090101 |
| N-(4-Chloro-2-nitro-phen-yl)methane-sulfonamide. | Acta crystallographica. Section E, Structure reports online 20081001 |
| Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. | Cardiology journal 20080101 |
| Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. | Biochemical pharmacology 20070801 |
| Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores. | Bioorganic & medicinal chemistry 20061001 |
| Expression and functional phenotype of mouse ERG K+ channels in the inner ear: potential role in K+ regulation in the inner ear. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20050921 |
| Structural determinants of HERG channel block by clofilium and ibutilide. | Molecular pharmacology 20040801 |
| A rapidly activating delayed rectifier K+ current regulates pacemaker activity in adult mouse sinoatrial node cells. | American journal of physiology. Heart and circulatory physiology 20040501 |
| Acceleration of human myoblast fusion by depolarization: graded Ca2+ signals involved. | Development (Cambridge, England) 20030801 |
| Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency. | Cardiovascular research 20030301 |
| Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels. | Molecular pharmacology 20011201 |
| Effects of the class III antiarrhythmic agent dofetilide (UK-68,798) on L-type calcium current from rabbit ventricular myocytes. | The Journal of pharmacy and pharmacology 20011201 |
| An amino acid residue whose change by mutation affects drug binding to the HERG channel. | FEBS letters 20011012 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.